BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Modern Pathology

• Publication date

  2012-01-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/modpathol.2011.211PMID 22282309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A multi-center study to evaluate the impact of germline BRCA1 and BRCA2 mutations on ovarian cancer survival

  2012cited by this paper
• Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.

  2011cited by this paper
• Abstract 2752: Genetic heterogeneity of ovarian cancer survival effects inBRCA1/2germline mutations: a large, multi-center study

  2011cited by this paper
• PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine

  2011cited by this paper
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

  2010cited by this paper
• The biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas

  2010cited by this paper
• Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?

  2010cited by this paper
• SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors

  2010cited by this paper
• Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

  2010cited by this paper
• Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

  2010cited by this paper
• Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.

  2010cited by this paper
• Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer

  2010cited by this paper
• The genesis and evolution of high-grade serous ovarian cancer

  2010cited by this paper
• Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment.

  2009cited by this paper
• The Sequence Alignment/Map format and SAMtools

  2009cited by this paper
• Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors

  2009cited by this paper
• Dramatic response to platinum in a patient with cancer with a germline BRCA2 mutation.

  2009cited by this paper
• Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss

  2009cited by this paper
• Intraepithelial T cells and tumor proliferation

  2009cited by this paper
• Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

  2009cited by this paper
• Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy: Results of an Open Noncomparative Phase 2 Multicenter Italian Study (After-6 Protocol 2)

  2009cited by this paper
• Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo

  2009cited by this paper
• Resistance to therapy caused by intragenic deletion in BRCA2

  2008cited by this paper
• Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

  2008cited by this paper
• Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies

  2008cited by this paper
• Therapeutic exploitation of tumor cell defects in homologous recombination.

  2008cited by this paper
• The impact of T‐cell immunity on ovarian cancer outcomes

  2008cited by this paper
• Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma.

  2008cited by this paper
• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

  2008cited by this paper
• "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

  2008cited by this paper
• Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer

  2008cited by this paper
• HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma

  2008cited by this paper
• Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

  2008cited by this paper
• A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.

  2007cited by this paper
• What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

  2007cited by this paper
• BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy

  2007cited by this paper
• BRCA-1 in Sporadic Epithelial Ovarian Cancer: Lessons Learned from the Genetics of Hereditary Disease

  2007cited by this paper
• Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

  2007cited by this paper
• Using specific cytotoxics with a targeted mind.

  2007cited by this paper
• Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.

  2007cited by this paper
• Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.

  2006cited by this paper
• Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential

  2006cited by this paper
• Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects

  2006cited by this paper
• The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.

  2006cited by this paper
• Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer

  2006cited by this paper
• What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)

  2006cited by this paper
• Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

  2005cited by this paper
• BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis

  2005cited by this paper
• Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.

  2003cited by this paper
• Improved survival in women with BRCA‐associated ovarian carcinoma

  2003cited by this paper
• Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

  2003cited by this paper
• Frequency of BRCA1 dysfunction in ovarian cancer.

  2002cited by this paper
• The relationship between the roles of BRCA genes in DNA repair and cancer predisposition.

  2002cited by this paper
• Inactivation of BRCA1 and BRCA2 in ovarian cancer.

  2002cited by this paper
• Identification of prognostic factors in advanced epithelial ovarian carcinoma.

  2001cited by this paper
• DNA double strand break repair in mammalian cells.

  2000cited by this paper
• The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin*

  2000cited by this paper
• Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.

  2000cited by this paper
• Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.

  1996cited by this paper
• Prognostic factors in malignant epithelial ovarian tumors.

  1983cited by this paper
• BIOINFORMATICS ORIGINAL PAPER

  year unknowncited by this paper
• Edinburgh Research Explorer Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma

  year unknowncited by this paper

• Impact of niraparib on reducing the platelet count in patients with ovarian cancer.

  2026cites this paper
• Prevalence of BRCA1/2 Mutation in High-Grade Non-Mucinous Ovarian Carcinoma.

  2025cites this paper
• Histopathological biomarkers in squamous cell carcinoma of the vulva: the prognostic relevance of tumor-infiltrating lymphocytes (TILs)—a retrospective study of 157 cases

  2025cites this paper
• Faecalibacterium Prausnitzii extracellular vesicles regulating macrophage differentiation via homologous recombination repair in colitis model.

  2025cites this paper
• Unraveling SET: Exploring ovarian high-grade serous carcinoma and its BRCA1/2 immunoexpression.

  2025cites this paper
• Treatment of ovarian cancer: From the past to the new era (Review)

  2025cites this paper
• Genome instability and crosstalk with the immune response

  2025cites this paper
• Epigenetics in Ovarian Cancer: A Review of Current Knowledge and Future Perspectives

  2025cites this paper
• Impact of Molecular Testing on the Surgical Management of Advanced Epithelial Ovarian Cancer.

  2024cites this paper
• GeSubNet: Gene Interaction Inference for Disease Subtype Network Generation

  2024cites this paper
• BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality

  2024influential citation
• Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?

  2024cites this paper
• Drug resistance in ovarian cancer: from mechanism to clinical trial

  2024cites this paper
• Association Between Germline BRCA1/2 Gene Variants and Clinicopathological Features of Ovarian Cancer

  2024cites this paper
• Prognostic Effects of RASSF1A, BRCA1, APC, and p16 Promoter Methylation in Ovarian Cancer: A Meta-Analysis

  2024cites this paper
• The Histopathological Findings of High-grade Serous Ovarian Carcinomas in Patients with BRCA Germline Mutations, Single Center Experience

  2024cites this paper
• Current data and future perspectives on DNA methylation in ovarian cancer (Review)

  2024cites this paper
• Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer

  2024cites this paper
• Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy

  2024cites this paper
• Investigating the suitability of in vitro cell lines as models for the major subtypes of epithelial ovarian cancer

  2023cites this paper
• NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma

  2023cites this paper
• Harnessing the Effects of Hypoxia-like Inhibition on Homology-directed DNA Repair.

  2023cites this paper
• Machine Learning Quantification of Intraepithelial Tumor-Infiltrating Lymphocytes as a Significant Prognostic Factor in High-Grade Serous Ovarian Carcinomas

  2023cites this paper
• A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer

  2023cites this paper
• Multi-scale characterisation of homologous recombination deficiency in breast cancer

  2023cites this paper
• Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer

  2023cites this paper
• DNA damage repair and cancer immunotherapy

  2023cites this paper
• T-Cell Receptor Repertoire Characteristics Associated with Prognostic Significance in High-Grade Serous Ovarian Carcinoma

  2023cites this paper
• Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches

  2023cites this paper
• Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study

  2022cites this paper
• Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment

  2022cites this paper
• Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer

  2022cites this paper
• The potential of PARP inhibitors in targeted cancer therapy and immunotherapy

  2022cites this paper
• Friend and foe: the regulation network of ascites components in ovarian cancer progression

  2022cites this paper
• Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation

  2022cites this paper
• Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer

  2022cites this paper
• PTEN and BRCA1 tumor suppressor loss associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in a murine model of ovarian cancer

  2022cites this paper
• Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes

  2022cites this paper
• Identification of CD8+ T Cell Related Biomarkers in Ovarian Cancer

  2022cites this paper
• Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance

  2022cites this paper
• Whole-Genome Sequencing Identifies PPARGC1A as a Putative Modifier of Cancer Risk in BRCA1/2 Mutation Carriers

  2022cites this paper
• A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.

  2022cites this paper
• Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial

  2022cites this paper
• p53 Immunohistochemistry and Mutation Types Mismatching in High-Grade Serous Ovarian Cancer

  2022cites this paper
• Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives

  2022cites this paper
• When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.

  2022cites this paper
• TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer

  2021cites this paper
• Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer

  2021influential citation
• Pharmacologic inhibition of ataxia telangiectasia and Rad3‐related (ATR) in the treatment of head and neck squamous cell carcinoma

  2021cites this paper
• Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study

  2021cites this paper
• The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers

  2021cites this paper
• Hereditary Breast and Ovarian Cancer: Current Concepts of Prevention and Treatment

  2021cites this paper
• Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer

  2021cites this paper
• Synergistic AHR Binding Pathway with EMT Effects on Serous Ovarian Tumors Recognized by Multidisciplinary Integrated Analysis

  2021cites this paper
• Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives

  2021cites this paper
• Targeting the DNA damage response in immuno-oncology: developments and opportunities

  2021cites this paper
• Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING

  2021influential citation
• TITLE : BRCA 1 promoter methylation and clinical outcomes in ovarian cancer : an individual patient data meta-analysis

  2021cites this paper
• Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity

  2021cites this paper
• DNA Damage Repair Inhibitor for Breast Cancer Treatment.

  2021cites this paper
• Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

  2021cites this paper
• T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review

  2021influential citation
• Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration

  2021cites this paper
• DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors

  2021cites this paper
• Pathology of Hereditary Breast and Ovarian Cancer

  2020cites this paper
• Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors

  2020cites this paper
• Genetic profiling of breast cancer: A case study on Wnt and BRCA pathways

  2020cites this paper
• Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma

  2020cites this paper
• Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma

  2020cites this paper
• PARP inhibition in the ovarian cancer patient: Current approvals and future directions.

  2020cites this paper
• Immunotherapy Advances for Epithelial Ovarian Cancer

  2020cites this paper
• BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis.

  2020cites this paper
• Alterations of DNA damage repair in cancer: from mechanisms to applications

  2020cites this paper
• Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-p53 Combined with Chemotherapy Treatment

  2020cites this paper
• Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma

  2020cites this paper
• Genetic Factors

  2020cites this paper
• Genomic profiling of platinum-resistant ovarian cancer: the road into druggable targets.

  2020cites this paper
• Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma

  2020cites this paper
• Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey

  2020cites this paper
• Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.

  2020cites this paper
• Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity, and Genomic Predictors of Drug Response.

  2020cites this paper
• Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements

  2020cites this paper
• Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?

  2020cites this paper
• Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling

  2020cites this paper
• ESMO Recommendations on Homologous Recombination Deficiency Testing to Predict PARP Inhibitor Benefit in Ovarian Cancer

  2020cites this paper
• Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes

  2020cites this paper
• ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.

  2020cites this paper
• Understanding genetic determinants of resistance to immune checkpoint blockers.

  2019cites this paper
• Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles

  2019cites this paper
• Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.

  2019cites this paper
• BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.

  2019cites this paper
• Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment.

  2019cites this paper
• Women’s cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics

  2019cites this paper
• Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations

  2019cites this paper
• Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy

  2019cites this paper
• Predicting E3 Ubiquitin Ligases as Possible Promising Biomarkers for Brain Tumors

  2019cites this paper
• Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?

  2019cites this paper
• Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches

  2019cites this paper
• DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes

  2019cites this paper
• Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease course.

  2019cites this paper